Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregul...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanner, Tamara, Wahezi, Dawn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387280/
https://www.ncbi.nlm.nih.gov/pubmed/32792288
http://dx.doi.org/10.1016/j.prrv.2020.07.003
_version_ 1783564089692258304
author Tanner, Tamara
Wahezi, Dawn M.
author_facet Tanner, Tamara
Wahezi, Dawn M.
author_sort Tanner, Tamara
collection PubMed
description The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response.
format Online
Article
Text
id pubmed-7387280
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73872802020-09-11 Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19 Tanner, Tamara Wahezi, Dawn M. Paediatr Respir Rev Review The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response. Elsevier Ltd. 2020-09 2020-07-29 /pmc/articles/PMC7387280/ /pubmed/32792288 http://dx.doi.org/10.1016/j.prrv.2020.07.003 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Tanner, Tamara
Wahezi, Dawn M.
Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
title Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
title_full Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
title_fullStr Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
title_full_unstemmed Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
title_short Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
title_sort hyperinflammation and the utility of immunomodulatory medications in children with covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387280/
https://www.ncbi.nlm.nih.gov/pubmed/32792288
http://dx.doi.org/10.1016/j.prrv.2020.07.003
work_keys_str_mv AT tannertamara hyperinflammationandtheutilityofimmunomodulatorymedicationsinchildrenwithcovid19
AT wahezidawnm hyperinflammationandtheutilityofimmunomodulatorymedicationsinchildrenwithcovid19

Ejemplares similares